Background and Regulatory Significance of FDA Accelerated Approval

On April 23, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval for Otameni (lunsotogene parvec-cwha), developed by Regeneron Pharmaceuticals (REGN), as a treatment for hearing loss caused by OTOF gene mutations. This marks a significant milestone in regulatory history as it is the first gene therapy to be launched on the market through the FDA Commissioner's National Priority Voucher (CNPV) pilot program. It is considered a successful example of a strong institutional incentive designed to encourage new drug developers to actively address rare diseases with high unmet needs, demonstrating its effectiveness in the field of gene therapy.

Mechanism of Action and CHORD Clinical Trial Data

Otameni is a one-time gene therapy that uses an adeno-associated virus (AAV) vector to directly deliver a normal gene encoding otoferlin, a protein essential for sound signal transmission, into the hair cells of the inner ear. The Phase 1/2 CHORD clinical trial (NCT05788536), which served as the primary basis for this approval, was conducted on pediatric patients aged 10 months to 16 years. In the trial, 80% of the patients showed an improvement of at least 70 decibels in pure-tone hearing threshold, enabling them to hear moderate-level conversational speech within 24 weeks of administration. The adverse effects were limited to transient infections and dizziness, similar to surgical complications, demonstrating a high safety profile.

Free Supply Policy and Market Pricing Changes

Regeneron announced an unusual commercialization strategy, offering Otameni free of charge to eligible patients in the United States. This is in stark contrast to the ultra-high pricing of existing gene therapies, which cost millions of dollars. This strategy aims to bypass the complex drug pricing negotiations and insurance coverage review processes, completely removing initial market entry barriers. However, while the drug itself is free, patients or healthcare systems will still have to bear the costs of anesthesia and surgical procedures, as well as post-operative care, similar to cochlear implant surgery. Therefore, the actual reduction in out-of-pocket expenses needs to be closely monitored in the future.

Restructuring of Competitive Landscape and Impact on Subsequent Players

Worldwide, approximately 200,000 people have OTOF-related hearing loss (DFNB9), which accounts for 1% to 5% of congenital hearing loss patients, making it an ultra-rare disease. In this small market, Regeneron's announcement of free supply has rapidly reshaped the competitive landscape, causing Sensorion, a French biotech company, to abruptly halt the development of its gene therapy candidate, SENS-501, and shift its pipeline to target GJB2 gene-related hearing loss, creating a significant impact. Although Eli Lilly (LLY) is pursuing its AK-OTOF pipeline, Regeneron, having achieved first-mover advantage, has secured a dominant market position in terms of accumulating clinical data and establishing trust among healthcare professionals.